-- ノバルティス（NVS）は、カナダ保健省が、補体3型糸球体症（C3G）の成人患者におけるタンパク尿の軽減を目的とした治療薬「ファバルタ」を承認したと発表しました。 C3Gは、免疫経路の過剰活性化によって引き起こされる稀な慢性腎疾患です。この過剰活性化により腎臓にタンパク質が蓄積し、炎症や損傷が生じ、最終的には腎機能の低下につながります。 今回の承認は、第III相臨床試験データに基づいています。このデータでは、6か月時点でタンパク尿が統計的に有意に減少し、その効果が1年間持続することが示されています。 ファバルタ（イプタコパン）は、免疫系の重要な構成要素（因子B）を阻害する経口薬で、C3Gの進行を促す有害な活性を抑制し、腎臓を保護します。
Price: $146.84, Change: $-1.01, Percent Change: -0.68%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We decrease our 12-month target by CAD35 to CAD370, as we value AEM using an EV/EBITDA of 8.4x applied to our 2027 EBITDA estimate, in line with AEM's three-year average forward EV/EBITDA of 8.4x and a premium to the peers' average of 5.3x. We increase our EPS estimates: 2026 by USD1.13 to USD14.65 and 2027 by USD2.71 to USD17.58. AEM delivered a strong Q1 with record operating margins driven by elevated gold prices and disciplined cost control. 2026 production guidance remains 3.3-3.5 million ounces with costs tracking to plan. AEM's balance sheet remains strong with $2.9B in net cash, supporting an industry-leading growth pipeline targeting 20%-30% production growth over the next decade through projects at Detour underground, Canadian Malartic expansion, Hope Bay, and Upper Beaver. The proposed Finland consolidation adds a potential 500k oz platform. Management plans to return 40% of free cash flow via dividends and an expanded $2B buyback program, while simultaneously funding high-return growth projects.
RBC Capital Markets in its CAD Weekly Soundbites (Rates & FX) note on Friday said an "event-rich" week "largely came as expected", with a "steady fiscal profile", the Bank of Canada delivering a "modestly hawkish hold" and first-quarter GDP "continuing to track above potential".The bank said the BoC's hawkish tilt reinforces its view for a gradual decline in USD/CAD in the long term. However, it added that recent BoC and Federal Reserve meetings suggest both will be on hold in the short term, leaving a range-bound bias on USD/CAD.In its rates view, RBC said the expected BoC hold was delivered this week, but the balance of changes tilted hawkish. The BoC modestly upgraded its GDP profile, noted the expected absorption of excess slack and said the neutral range discussion was slanted higher, even though the 2.25%-3.25% range was left unchanged.RBC said it maintains its long-held view that the base case is the BoC on hold in 2026, with hikes in 2027, but added that the chance of second-half hikes far exceeds the chance of a cut.On foreign exchange, RBC said this week's marginally hawkish BoC tilt reinforces its longer-run view for a gradual move lower in USD/CAD into next year, partly conditional on the BoC shifting to hikes in 2027, with risk in the second half of 2026.However, in the near term, the bank said it continues to see the pair range-bound, as central bank meetings suggest the BoC and the Fed are likely to be on hold in the coming months, keeping US-Canada rate differentials relatively stable. That should continue to act as a floor under USD/CAD, with the 1.3500 area seen as the bottom of the range.RBC added that a weekly close below 1.3598 has reasserted the downtrend in USD/CAD and favours a re-test of this year's lows at 1.3526 and 1.3482."Below there, the September 2024 low at 1.3420 would come into view. Initial resistance is located at 1.3598 and 1.3661, followed by 1.3728, with rallies to the latter two levels viewed as a selling opportunity," said George Davis, chief technical strategist at RBC Capital Markets.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We decrease our 12-month target by $6.50 to $7.50, on an EV/EBITDA of 5.5x our 2026 EBITDA estimate, below O-I's one-year average of 5.6x. We decrease our 2026 EPS by $0.58 to $1.25 and 2027 by $0.40 to $1.95. O-I's Fit to Win program achieved $35M in net savings during Q1 and is 50% of the way to its goal of $750M in benefits, a highlight of the quarter. O-I secured 15 new accounts in the quarter that should drive 2H 2026 volume 1.5% higher. We note that volumes were down 8% Y/Y; this trend improved in March, with volumes down only 2%. Management noted that the European segment was the primary driver of poor results, with a $68M decrease from the prior year attributable to softer demand and intense competition in the Southern European wine market. Inflation risks from conflicts in the Middle East are a major risk, potentially adding $75M-$100M in costs if prices remain elevated. We currently see 2027 EBITDA as flat vs. 2025 ($1.23B), but this view could improve if energy prices decrease in 2H 2026.